Rain Enhancement Technologies Holdco Inc (RAIN)

$RAIN what is this company

AMST stock is disrupting the healthcare sector using AI. No debt + micro float with a low dilution risk. 5+ coming and this should be a $20 stock. News coming any day! Bottomed out under $2 is a steal. The CEO loaded $1M worth of shares at $3 and never has sold! Insiders will load up again here at lows! $DRMA $STI $PLRZ $ZKIN $RAIN

$RAIN Coiling in a tight range, volume expansion could ignite this one

$RAIN Looks ready to push higher. Buyers are not letting it pull back much. Momentum remains strong.

$RAIN She is just about ready….

$RAIN this is ridiculous. Does way better AH than during market every single day

$RAIN ????

$RAIN will this ever have a good day?

$CAPT $HYFT $ITRM $NVO $RAIN CAPT: as predicted, gold is continuing its rise after a brief retrace. In the face of a weakening dollar, cryptocurrencies’ nascent, bear market, and threats of war, this could easily be one of the largest movers of the year. Currently mid $0.50’s. If 10:1 acquisition of the Montana Tunnel mines, we are looking at $4-5. Mineral assessment is pending, and it could be released any day. This will be key in determining the price target. Acquisition is set to be completed by the end of the first quarter. NASDAQ approved an extension based upon this pending acquisition with a deadline of March 31. I suspect we will hear something very very soon. HYFT: Just hit the reload zone. The chart is primed for rebound. They released groundbreaking news on an influenza vaccine breakthrough, and I suspect that they have an investor pool building up as we speak. I am looking for $4 per share, and it’s currently at $1.60.  ITRM: Flared almost 20% yesterday on low volume. There is not much liquidity left, and I am hopeful for a PBM update, as well as some sort of shining light at the end of the tunnel for this small bio pharmaceutical based out of Ireland. They have one of the only oral penem antibiotics approved by FDA, but have been constrained by a consistent lack of capital. Big Pharma is going to have a vested interest in picking up this company as cheap as possible, but we haven’t seen much in the way of share price movement to date. It looks good for a jump back to $.60 in my opinion. Currently at low $0.30s. NVO: earnings will be released on the fourth, and I am very bullish on this one. They had a full month of their newly FDA approved oral GLP-1 to add to the tally, and with 18,000 scripts in the first week of it’s release, I suspect a price target of $70 is reasonable. Currently trading at $58.88. RAIN: Oversold. Way oversold. No liquidity. Rapid correction incoming on this small startup with a solid financial foundation. I like this one for $8-9 per share, but earnings may send it up further. I suspect big things are coming here. Above all, DD and decide for yourself. NFA, as I’m not God’s gift to anything. GLTY.